ECDC data also show that 40% of adults in the EU and the European Economic Area (EEA) have received a third dose of Covid-19 vaccine. Cavaliers, on behalf of EZA, emphasized that it was important for EU citizens to complete a primary vaccination course with one of the EU-approved vaccines, while those who could receive a primary vaccine were encouraged to get vaccinated as soon as possible.
–
Regarding the omicron strain of the virus, the EZA emphasized that although it could more effectively circumvent at least some of the immune defense mechanisms, it has now been confirmed that Covid-19 vaccines still provide significant protection against hospitalization and severe disease progression, especially after receiving the vaccine.
–
Cavaliers said green regulators came together last week to discuss a global response to the wave of omicron disease.
—
and discuss possible vaccines against omicron and other types of Covid-19. Experts agreed that administering multiple doses of maintenance vaccines at appropriate intervals would not be a sustainable approach. The ESA emphasized that there was not enough experience to implement such an approach in the fight against other diseases, so it was difficult to predict the overall impact.
–
The ESA stressed that revaccination at short intervals may reduce antibody levels, as the immune system needs some time to develop a response. Over time, this approach may be less effective. If an additional booster vaccine is required in certain risk groups, it would be desirable to adjust it to seasonality, as is the case for influenza, in order to increase antibodies at the time when they are most needed.
–
He also stressed that
–
In the long term, a strategy will need to be developed for the types of vaccines needed to control Covid-19 in the future.
—
According to the ESA representative, this is an ongoing global debate. The strategy will require coordination between the many parties involved.
–
Cavali drew attention to a scientific study published on the EZA website about the effects of vaccination against Covid-19 during pregnancy. The study did not show any evidence of increased complications, miscarriage, risk of preterm birth, or adverse effects on unborn children receiving doses of the RNA messenger vaccine.
–
The results of the study show that Covid-19 vaccines are equally effective and reduce the risk of hospitalization and death in pregnant women. Mild to moderate adverse reactions have been reported in pregnant women following administration of the vaccine to the general population.
— .
